NASDAQ:MDVN - Medivation Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$81.44 0.00 (0.00 %)
(As of 05/23/2018 11:05 AM ET)
Previous Close$81.44
Today's Range$81.44 - $81.44
52-Week Range$26.41 - $81.48
Average Volume3.55 million shs
Market Capitalization$13.52 billion
P/E RatioN/A
Dividend YieldN/A

About Medivation (NASDAQ:MDVN)

Medivation logoMedivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Receive MDVN News and Ratings via Email

Sign-up to receive the latest news and ratings for MDVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity Ratio0.03
Current Ratio4.32
Quick Ratio4.32


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-195.92%
Return on Equity-225.98%
Return on Assets-108.55%


Outstanding Shares165,010,000

Medivation (NASDAQ:MDVN) Frequently Asked Questions

What is Medivation's stock symbol?

Medivation trades on the NASDAQ under the ticker symbol "MDVN."

How were Medivation's earnings last quarter?

Medivation Inc (NASDAQ:MDVN) posted its quarterly earnings data on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.27 by $0.02. The biopharmaceutical company earned $206 million during the quarter, compared to analysts' expectations of $214.52 million. Medivation had a negative return on equity of 225.98% and a negative net margin of 195.92%. Medivation's revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.58 EPS. View Medivation's Earnings History.

Has Medivation been receiving favorable news coverage?

News stories about MDVN stock have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medivation earned a news impact score of 0.19 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Medivation?

Shares of MDVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medivation's stock price today?

One share of MDVN stock can currently be purchased for approximately $81.44.

How big of a company is Medivation?

Medivation has a market capitalization of $13.52 billion. Medivation employs 628 workers across the globe.

How can I contact Medivation?

Medivation's mailing address is 525 Market St Fl 36, SAN FRANCISCO, CA 94105-2747, United States. The biopharmaceutical company can be reached via phone at +1-415-5433470.

MarketBeat Community Rating for Medivation (MDVN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  631 (Vote Outperform)
Underperform Votes:  381 (Vote Underperform)
Total Votes:  1,012
MarketBeat's community ratings are surveys of what our community members think about Medivation and other stocks. Vote "Outperform" if you believe MDVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Medivation (NASDAQ:MDVN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Medivation (NASDAQ:MDVN) Consensus Price Target History

Price Target History for Medivation (NASDAQ:MDVN)

Medivation (NASDAQ:MDVN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/9/2016BMO Capital MarketsReiterated RatingHoldN/AView Rating Details
9/28/2016CowenReiterated RatingHoldN/AView Rating Details
9/28/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
9/14/2016SunTrust BanksReiterated RatingNeutralN/AView Rating Details
8/23/2016Maxim GroupDowngradeBuy ➝ Hold$76.00 ➝ $81.50N/AView Rating Details
8/23/2016Credit Suisse GroupDowngradeOutperform ➝ Neutral$81.50N/AView Rating Details
8/23/2016Stifel NicolausDowngradeBuy ➝ HoldN/AView Rating Details
8/22/2016CitigroupDowngradeBuy ➝ Neutral$73.00 ➝ $81.50N/AView Rating Details
8/22/2016WedbushDowngradeOutperform ➝ Neutral$81.50N/AView Rating Details
8/22/2016Brean CapitalDowngradeBuy ➝ HoldN/AView Rating Details
8/22/2016BarclaysDowngradeOverweight ➝ Equal Weight$70.00 ➝ $81.00N/AView Rating Details
8/10/2016Leerink SwannSet Price TargetHold$64.00N/AView Rating Details
8/10/2016Jefferies GroupReiterated RatingHold$56.00 ➝ $60.00N/AView Rating Details
8/10/2016JMP SecuritiesDowngradeOutperform ➝ Market PerformN/AView Rating Details
(Data available from 5/23/2016 forward)


Medivation (NASDAQ:MDVN) Earnings History and Estimates Chart

Earnings by Quarter for Medivation (NASDAQ:MDVN)

Medivation (NASDAQ MDVN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$0.27$0.29$214.52 million$206.00 millionViewN/AView Earnings Details
5/5/2016Q116$0.23$0.11$197.01 million$182.50 millionViewListenView Earnings Details
2/25/2016Q415$0.28$0.29$373.85 million$377.74 millionViewListenView Earnings Details
11/5/2015Q315$0.33$0.35$236.70 million$260.70 millionViewN/AView Earnings Details
8/6/2015Q215$0.45$0.58$155.22 million$175.67 millionViewN/AView Earnings Details
5/7/2015Q115$0.27$0.17$149.00 million$129.20 millionViewN/AView Earnings Details
2/25/2015Q414$1.33$1.96$233.19 million$274.70 millionViewN/AView Earnings Details
11/6/2014Q314$0.84$0.96$182.00 million$200.48 millionViewN/AView Earnings Details
8/7/2014Q214$0.24$0.60$126.46 million$148.09 millionViewN/AView Earnings Details
5/8/2014Q114($0.09)($0.18)$94.64 million$87.19 millionViewN/AView Earnings Details
2/27/2014Q413($0.08)$0.03$72.68 million$96.61 millionViewN/AView Earnings Details
1/30/2014Q4($0.14)($0.43)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.14)($0.09)$60.45 million$60.03 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.21)($0.07)$59.35 million$70.15 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.45)($0.36)$38.54 million$46.15 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.52)($0.43)$34.36 million$37.16 millionViewN/AView Earnings Details
11/9/2012Q312($0.03)($0.06)$52.11 million$64.80 millionViewN/AView Earnings Details
8/9/2012$0.23($0.15)ViewN/AView Earnings Details
5/8/2012$1.19$0.01ViewN/AView Earnings Details
2/29/2012($0.25)($0.31)ViewN/AView Earnings Details
11/9/2011($0.31)($0.29)ViewN/AView Earnings Details
8/9/2011($0.25)($0.27)ViewN/AView Earnings Details
5/6/2011($0.24)($0.24)ViewN/AView Earnings Details
3/16/2011($0.17)($0.11)ViewN/AView Earnings Details
11/5/2010Q3 2010($0.05)($0.04)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.09)($0.05)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.11)($0.13)ViewN/AView Earnings Details
3/15/2010Q4 2009($0.14)($0.20)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.10)($0.11)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.09)($0.07)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.08)($0.05)ViewN/AView Earnings Details
3/16/2009Q4 2008($0.05)($0.07)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.14)($0.17)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.13)($0.16)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.09)($0.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Medivation (NASDAQ:MDVN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Medivation (NASDAQ MDVN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.54%
Institutional Ownership Percentage: 87.55%
Insider Trading History for Medivation (NASDAQ:MDVN)
Institutional Ownership by Quarter for Medivation (NASDAQ:MDVN)

Medivation (NASDAQ MDVN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/6/2016Andrew Kenneth William PowellSVPSell2,578$60.42$155,762.7628,517View SEC Filing  
5/6/2016Rick BierlyCFOSell10,340$59.76$617,918.4035,059View SEC Filing  
3/14/2016Dawn SvoronosDirectorSell6,000$38.90$233,400.0018,234View SEC Filing  
3/4/2016David HungCEOSell5,085$41.10$208,993.501,549,189View SEC Filing  
3/4/2016Mohammad HirmandInsiderSell1,525$41.10$62,677.5039,342View SEC Filing  
3/4/2016Rick BierlyCFOSell2,998$40.00$119,920.0040,959View SEC Filing  
2/4/2016David HungCEOSell6,350$31.18$197,993.001,504,654View SEC Filing  
1/19/2016Clarence Patrick MachadoDirectorSell75,000$37.34$2,800,500.0066,156View SEC Filing  
1/4/2016Joseph M LobackiInsiderSell3,065$46.50$142,522.5019,365View SEC Filing  
12/14/2015W Anthony VernonDirectorBuy15,000$40.69$610,350.0014,770View SEC Filing  
12/3/2015David HungCEOSell10,950$43.10$471,945.001,511,004View SEC Filing  
12/3/2015Mohammad HirmandInsiderSell1,075$43.40$46,655.0031,113View SEC Filing  
9/25/2015Clarence Patrick MachadoDirectorSell71,980$42.36$3,049,072.8066,156View SEC Filing  
9/8/2015Dawn SvoronosDirectorSell3,100$89.15$276,365.0012,117View SEC Filing  
6/4/2015Clarence Patrick MachadoDirectorSell36,000$117.43$4,227,480.00View SEC Filing  
5/20/2015Rick BierlyCFOSell1,000$130.00$130,000.00View SEC Filing  
5/5/2015Rick BierlyCFOSell1,615$125.00$201,875.00View SEC Filing  
5/4/2015Rick BierlyCFOSell2,170$124.70$270,599.00View SEC Filing  
4/15/2015Rick BierlyCFOSell3,000$132.20$396,600.00View SEC Filing  
3/16/2015Jennifer J RhodesInsiderSell1,390$130.92$181,978.80View SEC Filing  
3/2/2015David HungCEOSell100,891$120.83$12,190,659.53View SEC Filing  
3/2/2015Dawn SvoronosDirectorSell3,350$119.75$401,162.50View SEC Filing  
3/2/2015Jennifer J RhodesInsiderSell2,000$122.00$244,000.00View SEC Filing  
2/27/2015Kathryn E FalbergDirectorBuy25,000$117.67$2,941,750.00View SEC Filing  
2/26/2015David HungCEOSell19,109$120.12$2,295,373.08View SEC Filing  
2/26/2015Jennifer J RhodesInsiderSell3,089$119.29$368,486.81View SEC Filing  
2/4/2015David HungCEOSell3,190$100.48$320,531.20View SEC Filing  
1/27/2015Clarence Patrick MachadoDirectorSell36,000$105.32$3,791,520.00View SEC Filing  
1/20/2015David HungCEOSell100,000$108.14$10,814,000.00View SEC Filing  
12/3/2014Clarence Patrick MachadoDirectorSell1,580$113.00$178,540.00View SEC Filing  
12/3/2014David HungCEOSell5,420$113.00$612,460.00View SEC Filing  
9/18/2014Lynn SeelyInsiderSell55,000$98.47$5,415,850.00View SEC Filing  
9/9/2014Lynn SeelyInsiderSell20,000$94.60$1,892,000.00View SEC Filing  
8/27/2014Lynn SeelyInsiderSell20,000$89.42$1,788,400.00View SEC Filing  
8/13/2014Lynn SeelyInsiderSell20,000$83.62$1,672,400.00View SEC Filing  
8/12/2014Lynn SeelyInsiderSell25,500$83.02$2,117,010.00View SEC Filing  
7/22/2014Lynn SeelyInsiderSell7,500$73.96$554,700.00View SEC Filing  
7/2/2014Lynn SeelyInsiderSell12,000$79.02$948,240.00View SEC Filing  
6/18/2014Lynn SeelyInsiderSell15,000$74.75$1,121,250.00View SEC Filing  
2/18/2014Clarence Patrick MachadoCFOSell40,000$82.79$3,311,600.0030,830View SEC Filing  
2/11/2014Clarence Patrick MachadoCFOSell40,000$80.83$3,233,200.0030,830View SEC Filing  
2/5/2014Clarence Patrick MachadoCFOSell40,000$73.46$2,938,400.0030,830View SEC Filing  
1/28/2014Clarence Patrick MachadoCFOSell40,000$75.43$3,017,200.0030,830View SEC Filing  
1/27/2014David HungCEOSell150,000$73.50$11,025,000.00950,204View SEC Filing  
1/21/2014Clarence Patrick MachadoCFOSell40,000$76.29$3,051,600.0030,830View SEC Filing  
1/21/2014Jennifer RhodesInsiderSell14,000$76.28$1,067,920.006,000View SEC Filing  
12/3/2013Clarence Patrick MachadoCFOSell5,425$62.66$339,930.5030,830View SEC Filing  
12/3/2013David HungCEOSell15,050$62.61$942,280.50950,204View SEC Filing  
10/24/2013Cheryl CohenInsiderSell50,000$64.25$3,212,500.00View SEC Filing  
8/2/2013Cheryl CohenInsiderSell25,000$59.31$1,482,750.0025,439View SEC Filing  
7/5/2013David HungCEOSell30,885$55.45$1,712,573.25View SEC Filing  
7/3/2013Cheryl CohenInsiderSell25,000$54.01$1,350,250.00View SEC Filing  
10/4/2012David HungCEOSell50,000$57.92$2,896,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Medivation (NASDAQ MDVN) News Headlines

5 Cannabis Companies To Watch As Legalization Approaches5 Cannabis Companies To Watch As Legalization Approaches - May 18 at 9:07 AM
PARP Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018 - ResearchAndMarkets.comPARP Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018 - - May 11 at 5:32 PM
Endocyte Provides First Quarter 2018 Financial Results and Operational UpdateEndocyte Provides First Quarter 2018 Financial Results and Operational Update - May 9 at 8:42 AM
Verastem Oncology Reports First Quarter 2018 Financial ResultsVerastem Oncology Reports First Quarter 2018 Financial Results - May 3 at 5:08 PM
PARP Drugs Help Some Breast Cancer Patients, But Theyre No Magic BulletPARP Drugs Help Some Breast Cancer Patients, But They're No Magic Bullet - April 30 at 5:01 PM
REVOLUTION Medicines Raises $56 Million Series B FinancingREVOLUTION Medicines Raises $56 Million Series B Financing - April 24 at 8:37 AM
Promethera Biosciences Announces Updates to its Board of Directors Charles L. Dimmler, III elected as new Chairman ...Promethera Biosciences Announces Updates to its Board of Directors Charles L. Dimmler, III elected as new Chairman ... - April 6 at 8:50 AM
4 Healthcare Megatrends for Investors4 Healthcare Megatrends for Investors - April 5 at 10:39 AM
Is Pfizer Inc. a Buy?Is Pfizer Inc. a Buy? - April 1 at 8:39 AM
Reckitt Shares Jump as It Passes on Pfizer Consumer AuctionReckitt Shares Jump as It Passes on Pfizer Consumer Auction - March 24 at 5:01 PM
Analyzing Deciphera Pharmaceuticals (DCPH) & Medivation (MDVN)Analyzing Deciphera Pharmaceuticals (DCPH) & Medivation (MDVN) - December 15 at 1:30 AM
Paratek Pharmaceuticals Set To Explode As The Holy Grail Of Antibiotics Omadacycline Nears FDA Approval - Seeking AlphaParatek Pharmaceuticals Set To Explode As The Holy Grail Of Antibiotics Omadacycline Nears FDA Approval - Seeking Alpha - December 13 at 9:40 AM
Medivation (MDVN) and Its Peers Head to Head ContrastMedivation (MDVN) and Its Peers Head to Head Contrast - December 12 at 3:24 AM
Medivation Founder Takes Helm at Axovant, Shares SpikeMedivation Founder Takes Helm at Axovant, Shares Spike - October 6 at 10:22 AM
Contrasting Summit Therapeutics PLC (SMMT) and Medivation (MDVN)Contrasting Summit Therapeutics PLC (SMMT) and Medivation (MDVN) - August 17 at 4:50 AM
Evercore: Underfollowed Firm Has Great Potential - Seeking AlphaEvercore: Underfollowed Firm Has Great Potential - Seeking Alpha - August 9 at 4:31 AM
Clovis Looks Vastly Overpriced - Seeking AlphaClovis Looks Vastly Overpriced - Seeking Alpha - March 28 at 10:29 AM
Clovis Looks Vastly OverpricedClovis Looks Vastly Overpriced - March 27 at 6:01 PM
Clovis, Tesaro Soar on Astrazeneca Phase Three NewsClovis, Tesaro Soar on Astrazeneca Phase Three News - February 17 at 2:34 PM
Pfizer May Be Another IBMPfizer May Be Another IBM - February 3 at 7:12 PM
Recent Pfizer Press ReleasesRecent Pfizer Press Releases - January 31 at 7:22 PM
Pfizer quarterly revenue slips 3 percentPfizer quarterly revenue slips 3 percent - January 31 at 7:22 PM
The Best Biopharma CEOs of 2016 Are...The Best Biopharma CEOs of 2016 Are... - December 19 at 10:32 AM
After FDA Approval, Merck Posts Better-Than-Expected EarningsAfter FDA Approval, Merck Posts Better-Than-Expected Earnings - October 25 at 11:10 AM
Pfizer (PFE) Closes Medivation (MDVN) Acquisition - StreetInsider.comPfizer (PFE) Closes Medivation (MDVN) Acquisition - - September 28 at 11:02 AM
MEDIVATION, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or DisMEDIVATION, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or Dis - September 28 at 11:01 AM

SEC Filings

Medivation (NASDAQ:MDVN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Medivation (NASDAQ:MDVN) Income Statement, Balance Sheet and Cash Flow Statement


Medivation (NASDAQ MDVN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.